Northern Trust’s Avidity Biosciences RNAM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-1,019,087
Closed -$73.5M 4513
2025
Q4
$73.5M Buy
1,019,087
+44,031
+5% +$2.84M 0.01% 889
2025
Q3
$42.5M Sell
975,056
-21,999
-2% -$889K 0.01% 1232
2025
Q2
$28.3M Sell
997,055
-21,427
-2% -$639K ﹤0.01% 1441
2025
Q1
$30.1M Sell
1,018,482
-60,952
-6% -$1.9M ﹤0.01% 1391
2024
Q4
$31.4M Buy
1,079,434
+108,303
+11% +$4.53M ﹤0.01% 1422
2024
Q3
$44.6M Buy
971,131
+211,059
+28% +$9.16M 0.01% 1102
2024
Q2
$31M Buy
760,072
+88,744
+13% +$2.55M 0.01% 1278
2024
Q1
$17.1M Buy
671,328
+8,460
+1% +$133K ﹤0.01% 1691
2023
Q4
$6M Buy
662,868
+22,524
+4% +$151K ﹤0.01% 2391
2023
Q3
$4.09M Sell
640,344
-11,156
-2% -$96.1K ﹤0.01% 2565
2023
Q2
$7.23M Buy
651,500
+50,093
+8% +$628K ﹤0.01% 2278
2023
Q1
$9.23M Buy
601,407
+73,552
+14% +$1.62M ﹤0.01% 2070
2022
Q4
$11.7M Buy
527,855
+46,947
+10% +$700K ﹤0.01% 1895
2022
Q3
$7.85M Buy
480,908
+23,994
+5% +$459K ﹤0.01% 2161
2022
Q2
$6.64M Buy
456,914
+83,520
+22% +$1.24M ﹤0.01% 2322
2022
Q1
$6.9M Sell
373,394
-5,847
-2% -$99.3K ﹤0.01% 2381
2021
Q4
$9.01M Buy
379,241
+24,011
+7% +$573K ﹤0.01% 2308
2021
Q3
$8.75M Buy
355,230
+83,960
+31% +$1.82M ﹤0.01% 2376
2021
Q2
$6.7M Sell
271,270
-16,409
-6% -$382K ﹤0.01% 2647
2021
Q1
$6.27M Buy
287,679
+95,456
+50% +$2.34M ﹤0.01% 2605
2020
Q4
$4.91M Sell
192,223
-1,204
-0.6% -$35.1K ﹤0.01% 2693
2020
Q3
$5.45M Buy
+193,427
New +$5.59M ﹤0.01% 2488

Other funds holding RNAM

Northern Trust's RNAM Position: Q1 2026 in Review

Northern Trust sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 1,019,087 shares — an estimated $73.5M sold.

Northern Trust first reported a position in RNAM in Q3 2020 and held it in 22 quarters. The position peaked at $73.5M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

  • Northern Trust reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
  • Northern Trust sold 1,019,087 Avidity Biosciences shares in Q1 2026, an estimated $73.5M.
  • Northern Trust first reported a position in Avidity Biosciences in Q3 2020 and held it in 22 quarters.
  • Northern Trust's Avidity Biosciences position peaked at $73.5M in Q4 2025.
  • 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.